First-In-Class, Patented Topical Muscle Relaxant
Redefining treatment for acute musculoskeletal pain and spasms through a targeted, localized therapeutic approach.
Introduction to Prima Innovations LLC
Prima Innovations LLC is a pre-clinical stage pharmaceutical company developing a first-in-class topical muscle relaxant with antispasmodic action designed to target muscle spasms at their source. Prima has established proof-of-principle, based on four different animal models and has established mechanism of action. Headquartered in Wayne, New Jersey, our company is pioneering a localized therapeutic approach for acute musculoskeletal pain relief and chronic muscle spasm conditions.
Traditional oral skeletal muscle relaxants often act through the central nervous system (CNS), specifically through sodium channel present in neurons, NaV 1.8; which may lead to systemic side effects such as drowsiness and cognitive impairment. Prima Innovations is developing an alternative — a locally acting proprietary muscle relaxant drug, PI-111, that works specifically through sodium channel present in muscles, NaV 1.4. That way Prima’s drug eliminates all the systemic side effects such as drowsiness and cognitive impairment.
By focusing on localized delivery, we aim to redefine how painful muscle spasms of back, neck, shoulder, leg etc. are treated in quick and efficient manner, with minimal systemic exposure.
Why a Localized Muscle Relaxant Matters
Millions of patients worldwide experience muscle spasms associated with acute injury, chronic musculoskeletal disorders, spasticity-related conditions, and mechanical back or neck strain. Current systemic medications for painful muscle spasms often require oral dosing that circulates throughout the body before reaching muscle tissue.
Prima Innovations is developing a topical skeletal muscle relaxant intended to act directly at the site of spasm. This targeted approach is designed to:
Direct Delivery
Deliver antispasmodic medication directly to affected muscle groups
Effective Relief
Support quick effective pain relief through localized pharmacologic action, usually within 10 minutes
Differentiated
Provides a unique differentiated mechanism compared to centrally acting agents
Unmet Need
Address an unmet need in muscle spasm treatment
Our investigational compound is being developed to exhibit antispasmodic effect at the muscle level rather than relying primarily on central nervous system modulation. This scientific strategy represents a meaningful advancement in muscle relaxant drug development.
Lead Program
Our Investigational Therapy: A First-in-Class Approach
Prima Innovations’ lead program is focused on developing a fast-acting muscle relaxant formulated for topical administration. Unlike over-the-counter drugs like menthol or camphor which are counterirritants or analgesic creams like diclofenac, our therapy is designed as a pharmaceutical-grade antispasmodic medication with a defined mechanism of action at cellular level.
We have established robust Proof-of-Principle using four animal models:
- Rota Rod Study (in vivo)
- Open Field Test (in vivo)
- Muscle Twitch Study (in vivo)
- Isolated Muscle Study (in vitro)
Further, we have also established mechanism of action of PI-111, which is temporary inhibition of voltage gated NaV 1.4, sodium channel.
Our investigational therapy is being developed to potentially address:
Neck pain relief
Back pain muscle relaxant needs
Leg muscle spasm relief
Spasticity treatment medication applications
Pain associated with muscle hyperactivity
As a pre-clinical stage pharmaceutical program, further regulatory review and clinical studies will determine safety and efficacy outcomes. Prima Innovations is committed to advancing its development program through rigorous scientific validation.
Scientific Foundation and Innovation
The science behind Prima Innovations is grounded in pharmacology, muscle physiology, and targeted drug delivery systems. By focusing on local muscle pathways involved in spasm generation, our approach is intended to interrupt abnormal muscle contraction directly at its origin by temporarily blocking voltage gated sodium channel, NaV 1.4, present in the neuromuscular junctions of the skeletal muscles.
Key differentiators of our technology include:
- Topical delivery optimized for dermal penetration
- Targeted action within skeletal muscle tissue
- Pharmaceutical development pathway aligned with regulatory standards
- Multi-Layered Patent Strategy
Our intellectual property portfolio supports the advancement of a novel antispasmodic muscle pain relief platform that may expand future pipeline opportunities.
Clinical Development and Growth Strategy
Prima Innovations is on the verge of initiating IND enabling studies. These studies will have four parts as follows.
- Finalize formulation and package, along with IVPT studies
- Toxicology evaluations
- Complete animal efficacy studies
- Clinical model development
Many of these studies or work will be done in parallel, including filing for Interact meeting package and pre-IND meeting package
We are actively seeking strategic partnerships and investor collaboration to accelerate clinical development and commercialization planning.
Why Partner with Prima Innovations
Prima Innovations represents an opportunity at the intersection of pharmaceutical innovation and large unmet medical need. The global demand for effective pain relief and muscle spasm treatment continues to grow, yet few pharmaceutical solutions target muscle tissue directly.
Our company offers:
- A differentiated mechanism of action
- Patent-protected pharmaceutical innovation
- Scalable platform technology with potential to launch multiple products
- Strong scientific leadership
- Investor-focused growth vision
We believe our approach has the potential to reshape how clinicians think about muscle relaxant therapy.
Frequently Asked Questions
Q:
What makes Prima Innovations’ muscle relaxant different?
Our investigational therapy is designed as a topical muscle relaxant with antispasmodic action that works locally within muscle tissue rather than primarily targeting the central nervous system.
Q:
Is the product FDA approved?
No. We are preparing to file Investigational New Drug (IND) application to conduct clinical trials to eventually get approval from the FDA.
Q:
What conditions could this therapy address?
The development program is focused on muscle spasm treatment, acute musculoskeletal pain relief, back and neck muscle spasm relief, and potential spasticity treatment medication applications.
Q:
How can investors connect with Prima Innovations?
Investors and strategic partners can contact Dr. Mandar Shah directly using the information below to schedule meetings or request further materials.
Contact Prima Innovations LLC
To learn more about our pre-clinical stage topical muscle relaxant drug or to discuss partnership opportunities, please reach out directly. Prima Innovations welcomes collaboration with investors, research institutions, and strategic pharmaceutical partners committed to advancing innovative muscle spasm solutions.
Thank you for contacting us.We’ll get back to you as soon as possible.
We got it.
Ready to begin?
You don’t have to take the next step alone.
Reaching out is the first step.
